Remifentanil Effect on Burst Suppression Ratio

Launched by UNIVERSITY OF CHILE · Jan 24, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how a medication called remifentanil may help enhance the effects of another medication, propofol, during anesthesia. Specifically, the study will look at whether remifentanil makes it easier for propofol to create a state called "burst suppression," which is important for safely managing anesthesia in patients undergoing elective surgeries. Participants will be adults aged 18 to 60 who are classified as being at low or intermediate risk for surgery and who need general anesthesia.

To take part in the trial, individuals must be generally healthy with no serious neurological or psychiatric conditions and not taking certain medications that could affect the study. During the trial, participants will receive both remifentanil and propofol while being closely monitored. The researchers will adjust the levels of these medications to see how they work together to achieve burst suppression. This study is still in the planning stages and is not yet recruiting participants, but it aims to gather valuable information to improve anesthesia practices in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • American Society of Anesthesiology I or II
• • Elective surgery of low or intermediate risk
• Exclusion Criteria:
• • Neurological disease
• • Psychiatric disease
• • Use of psychoactive drugs or opioids
• • Altered basal state of consciousness
• • Allergy to propofol
• • Body mass index \> 35 kg/m2
• • Pre-existing renal, cardiac and/or hepatic dysfunction
• • Patient's refusal to participate